Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK

Size: px
Start display at page:

Download "Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK"

Transcription

1 Chairs Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK Faculty members Andreas Brandl, Charité Campus Berlin, Berlin, DE James Coakes, Basingstoke and North Hampshire Hospital, Basingstoke, UK Marcello Deraco, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT Jesús Esquivel, Eastern Regional Medical Center, Philadelphia, Pennsylvania, US Olivier Glehen, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon, FR Diane Goéré, Institut Gustave Roussy, Villejuif, FR Gabriel Glockzin, Klinikum Bogenhausen, Munich, DE Santiago González-Moreno, Centro Oncológico MD Anderson, Madrid, SP Chirsthardt Köhler, Asklepios Klinik, Hamburg, DE Akash Mehta, Basingstoke and North Hampshire Hospital, Basingstoke, UK Faheez Mohamed, Basingstoke and North Hampshire Hospital, Basingstoke,UK Aviram Nissan, Hadassah Medical Center, Jerusalemn, IL Jörg Pelz, University of Wuerzburg, Wuerzburg, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Paul Sugarbaker, Washington Cancer Center, Washington, US Andrew Thrower, Basingstoke and North Hampshire Hospital, Basingstoke, UK Peter Thuss-Patience, Charité Campus Virchow-Klinikum, Berlin, DE Kurt Van der Speeten, Ziekenhuis Oost-Limburg, Genk, BE Vic Verwaal, Aarhus University Hospital, DK Haney Youssef, Heart of England NHS Foundation Trust, Birmingham, UK

2 Programme Thursday 2 nd March 13:00 Introduction B. Rau, T. Cecil CRS and HIPEC - Chairs: B. Rau, T. Cecil History and evolution of CRS and HIPEC P. Sugarbaker What is it all about? (video of CRS surgery) T. Cecil Rationale for HIPEC K. Van der Speeten Preoperative radiological staging A. Thrower Role of staging laparoscopy in case selection J. Esquivel Coffee break Perioperative management Chairs: T. Cecil, O. Glehen Patient selection and work up for CRS and HIPEC F. Mohamed Making HIPEC safe for patients and staff D. Goéré PCI, CCR and PSS - Understanding the language of peritoneal malignancy G. Glockzin Anaesthetic and critical care management of CRS and HIPEC J. Coakes 17: Prevention and management of postoperative complications F. Quenet

3 Overview of international guidelines for CRS and HIPEC S. Santiago González-Moreno Avoiding the learning curve? H. Youssef Dinner Friday 3 rd March Hands on session Tutors: T. Cecil, M. Deraco, J. Esquivel, O. Glehen, G. Glockzin, D. Goéré, S. González-Moreno, C. Köhler, A. Nissan, J. Pelz, F. Quenet, B. Rau, P. Sugarbaker, K. Van der Speeten, V. Verwaal,, F. Mohamed, H.Youssef 08: Anatomical structure in animal L. K. Groebler Comparative anathomy in humans and animals B. Rau Right upper quadrant Parietal peritoneum falciform ligament cholecystectomy and lesser omentum Coffee Break Left upper quadrant to include stripping of diaphragm left parietal peritoneum splenectomy distal pancreatectomy to include discussion on strategy for partial and total gastrectomy Lunch Pelvis peritoneum anterior resection Open and closed HIPEC Coffee Break

4 Discussion with the experts Chairs: K. Van der Speeten, F. Mohamed Summary of CRS and HIPEC (video) M. Deraco MDT discussion Colorectal A. Nissan Pseudomyxoma T. Cecil Gastric O. Glehen Ovarian C. Köhler Mesothelioma A. Brandl Rare case J. Pelz Saturday 4th march Frequent Indications and systemic treatment Chairs: J. Esquivel, G. Glockzin Pseudomyxoma Peritonei - What organs have to be removed and at what cost? F. Mohamed Malignant Peritoneal Mesothelioma and Primay Peritoneal Carcinoma selection and technique M. Deraco Peritoneal Metastases from Ovarian Cancer Timing of surgery and role of HIPEC C. Köhler

5 Peritoneal Metastases from Gastric Cancer. Selecting the winners and improving outcomes O. Glehen Peritoneal Metastases from Colorectal Cancer H. Youssef Ongoing CRS and HIPEC clinical trials in GI Cancer V. Verwaal Timing and role of systemic chemotherapy in Peritoneal Metastases of Gastrointestinal Origin P. Thuss-Patience Coffee Break Controversies in Peritoneal Malignancy - Chairs: T. Cecil, M. Deraco Gynecological surgery in peritoneal malignancy do we always have to take the ovaries? A. Mehta Are liver and lung metastases a contraindication to CRS and HIPEC K. Van der Speeten Debate P. Sugarbaker vs J. Esquivel: This House believes there is no place for Laparoscopic CRS and HIPEC For Paul Sugarbaker (vote) Against Jesús Esquivel (vote) Debate and final votes Post-test Conclusions

Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University

More information

Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Chairs Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Salah-Eddin Al-Batran, Institut für Klinisch-Onchologische

More information

Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)

Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS) Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS) 19-21 MARCH 2015 HAMBURG EUROPEAN SCHOOL OF PERITONEAL SURFACE ONCOLOGY Management of Hyperthermic Intraperitoneal

More information

International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program

International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program Day 1 Program Wednesday, 9 of August, 2017 Regional Oncology Center, Irkutsk Conference Hall 8.00-8.30 Registration of participants 8.30-8.50 Opening conference Welcome Gouverneur (Sergey Levchenko) Welcome

More information

PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,

PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11, 11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France www.psogi2018.com 9THSATURDAY 8TH 2SUNDAY Saturday, September 8

More information

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September

More information

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September

More information

10 th International Congress on Peritoneal Surface Malignancies

10 th International Congress on Peritoneal Surface Malignancies 10 th International Congress on Peritoneal Surface Malignancies November 17 19, 2016 Omni Shoreham Hotel Washington, DC Course Director: MedStar Washington Hospital Center Washington, DC www.psogi2016.com

More information

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large

More information

Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei

Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM

More information

FINAL SCIENTIFIC PROGRAMME

FINAL SCIENTIFIC PROGRAMME FINAL SCIENTIFIC PROGRAMME AGENDA Day 1 Speaker Chairpersons 8:30 AM 8:45 AM 8:45 AM 9:00 AM Intraperitoneal chemotherapytypes, techniques, tips Choice of drugs and carrier solutions for intraperitoneal

More information

CURRICULUM VITAE 2005

CURRICULUM VITAE 2005 CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr

More information

Colorectal peritoneal metastases and IMPACT

Colorectal peritoneal metastases and IMPACT Colorectal peritoneal metastases and IMPACT Vicki Pleavin-Evans Peritoneal Malignancy Clinical Nurse Specialist PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire

More information

Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2

Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2 Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal

More information

Pre-operative assessment of patients for cytoreduction and HIPEC

Pre-operative assessment of patients for cytoreduction and HIPEC Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive

More information

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL)

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL) Chairs Jakub Kenig, Jagiellonian University Medical College, Kraków (PL) Riccardo A. Audisio, Whiston Hospital, University of Liverpool, Liverpool, (UK) Tomasz Grodzicki, Jagiellonian University Medical

More information

SIOP. 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy June 2018 nauen Ot Groß Behnitz (Berlin area), Germany.

SIOP. 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy June 2018 nauen Ot Groß Behnitz (Berlin area), Germany. SIOP SIOP Europe the European Society for Paediatric Oncology 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy 16-21 June 2018 nauen Ot Groß Behnitz (Berlin area), Germany Chairs: S. Bielack, DE

More information

HIPEC AND COMPLICATED COLORECTAL SURGERY

HIPEC AND COMPLICATED COLORECTAL SURGERY HIPEC AND COMPLICATED COLORECTAL SURGERY START: May 16th, 2014 END: May 17th, 2014 LOCATION: Vilnius, Lithuania OFFICIAL LANGUAGE: English Translation services will not be provided CERTIFICATION: Vilnius

More information

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA

More information

Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer

Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned

More information

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R. MASTERCLASS 6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY Held with the support of 11-16 June 2016 Berlin, Germany Chairs: A. Eggert, DE B. Morland, UK R. Riccardi, IT INTRODUCTION ESO and SIOP-Europe

More information

Peritoneal dissemination is a common manifestation of disease

Peritoneal dissemination is a common manifestation of disease ORIGINAL ARTICLE Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Dario Baratti, MD, Shigeki Kusamura,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, pancreatic ductal, laparoscopic distal pancreatectomy for, 61 Adrenal cortical carcinoma, laparoscopic adrenalectomy for, 114

More information

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management

More information

Gastrointestinal Oncology

Gastrointestinal Oncology 2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting

More information

Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal

More information

Contents. Part 1. Peritoneal Carcinomatosis: Basic Concepts

Contents. Part 1. Peritoneal Carcinomatosis: Basic Concepts Contents Part 1. Peritoneal Carcinomatosis: Basic Concepts 1. Structure and Function of Mesothelial Cells... 1 Introduction... 1 Structure of Mesothelial Cells... 1 Mesothelial Cell Functions... 3 Slippery

More information

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,

More information

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY 10-13 November 2018 Yerevan, Armenia Chairs: G. Curigliano, IT F. Peccatori, IT Host Chair: G. Tamamyan, AM Held in collaboration with MASTERCLASS AIMS AND OBJECTIVES

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective

More information

PROGRAM. 13 th ICRCC Congress on Colorectal Cancer Final Programm Friday, 28 September 2018

PROGRAM. 13 th ICRCC Congress on Colorectal Cancer Final Programm Friday, 28 September 2018 13 th ICRCC Congress on Colorectal Cancer 2018 Final Programm Friday, 28 September 2018 07:30 08:00 Registration 08:00 08:15 Opening Ceremony Prof. K.H. Link, em. Director of Surgical Center Asklepios,

More information

Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS

Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Department of surgical oncology, Carl von Hess hospital, Hammelburg, Germany www.klinik-hammelburg.de

More information

1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011

1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011 International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic

More information

Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal

More information

ESSO Advanced Course on Primary Liver Tumours

ESSO Advanced Course on Primary Liver Tumours ESSO Advanced Course on Primary Liver Tumours 24-25 April 2014 LIVERPOOL (UK) Endorsed by ESSO Advanced Course on Primary Liver Tumours Chair Hassan Malik, University Hospital Aintree NHS Trust, Liverpool,

More information

tumor. CRS? HIPEC was well tolerated in our selected patients with PC, some of whom had improved survival.

tumor. CRS? HIPEC was well tolerated in our selected patients with PC, some of whom had improved survival. Ann Surg Oncol (29) 16:345 351 DOI 1.45/s1434-8-226-2 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients

More information

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin Gastroenterology Research and Practice Volume 2012, Article ID 981245, 5 pages doi:10.1155/2012/981245 Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei

More information

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346 Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy

More information

This meeting has been made possible by an independent grant from Roche.

This meeting has been made possible by an independent grant from Roche. This meeting has been made possible by an independent grant from Roche. This event has been created in collaboration between the University of Milan and ecancer. MILAN SUMMIT ON PRECISION MEDICINE AGENDA

More information

CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017

CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease

More information

Liver Surgery: from basics to advanced care VIENNA (AT)

Liver Surgery: from basics to advanced care VIENNA (AT) Liver Surgery: from basics to advanced care 07-08 S e p t e m b e r 2015 VIENNA (AT) Liver Surgery: from basics to advanced care Chair: Thomas Gruenberger, Rudolfstiftung Hospital Vienna, AT Co-Chairs

More information

Results of a French Multicentric Analysis

Results of a French Multicentric Analysis Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and

More information

Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500

More information

Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES

Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal

More information

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the

More information

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR

More information

Hepatobiliary and pancreatic procedures during cytoreductive surgery and HIPEC

Hepatobiliary and pancreatic procedures during cytoreductive surgery and HIPEC JBUON 2017; 22(5): 1338-1344 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Hepatobiliary and pancreatic procedures during cytoreductive surgery

More information

ESSO Advanced Course on UPPER GI Malignancy

ESSO Advanced Course on UPPER GI Malignancy ESSO Advanced Course on UPPER GI Malignancy In association with PSSO (Polish Society of Surgical Oncology) 18-19 October 2013 POZNÁN ESSO Advanced Course on Upper Gi Malignancy Course directors Chair:

More information

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis Vassos et al. World Journal of Surgical Oncology (2016) 14:42 DOI 10.1186/s12957-016-0804-x RESEARCH Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal (HIPEC) in patients with recurrent

More information

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources

More information

Surgical Oncology, Mercy Medical Center, Baltimore, MD

Surgical Oncology, Mercy Medical Center, Baltimore, MD Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients

More information

Computerized System for Staging Peritoneal Surface Malignancies

Computerized System for Staging Peritoneal Surface Malignancies Ann Surg Oncol (2016) 23:1454 1460 DOI 10.1245/s10434-015-4966-5 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Computerized System for Staging Peritoneal Surface Malignancies Paolo Sammartino, MD, PhD, Daniele

More information

THURSDAY, 9 JUNE 2016

THURSDAY, 9 JUNE 2016 COMMITTEE Dr. Peter Vorwald. Fundación Jiménez Díaz. Madrid. Dr. Gabriel Salcedo. Fundación Jiménez Díaz. Madrid. Dra. María Posada. Fundación Jiménez Díaz. Madrid. Dr. Damián García Olmo. Grupo Quirón

More information

EAES course on Advanced Laparoscopic GI Surgery Course. Riyadh, Saudi Arabia February 2016

EAES course on Advanced Laparoscopic GI Surgery Course. Riyadh, Saudi Arabia February 2016 EAES course on Advanced Laparoscopic GI Surgery Course Riyadh, Saudi Arabia 13-17 February 2016 The European Association for Endoscopic Surgery and King Saud University, College of Medicine King Khalid

More information

Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013

Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013 International Surgical Oncology Volume 2013, Article ID 461041, 5 pages http://dx.doi.org/10.1155/2013/461041 Research Article Quality of Life Study following Cytoreductive Surgery and Intraperitoneal

More information

CRS e HIPEC: Efficacia e Limiti

CRS e HIPEC: Efficacia e Limiti CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It

More information

Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery. Scientific Program

Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery. Scientific Program Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery Scientific Program Thursday, October 30 th 13:30 13:45 Official Opening Welcome

More information

Update on the management of malignant peritoneal mesothelioma

Update on the management of malignant peritoneal mesothelioma Review Article Update on the management of malignant peritoneal mesothelioma Paul H. Sugarbaker Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA Correspondence

More information

Optimal drugs for HIPEC in different tumors

Optimal drugs for HIPEC in different tumors JBUON 2015; 20 (Suppl. 1): S40-S46 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Optimal drugs for HIPEC in different tumors Eelco de Bree Department

More information

How to deal with patients with isolated peritoneal metastases

How to deal with patients with isolated peritoneal metastases ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal

More information

Information for health professionals - pseudomyxoma peritonei

Information for health professionals - pseudomyxoma peritonei Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive

More information

Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.

Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Dr. Pere Bretcha Boix Plataforma de Oncología Hospital quironsalud Torrevieja 1 20-year survival of 70% 2 Appendiceal Neoplasms

More information

POLICIES AND PROCEDURE MANUAL

POLICIES AND PROCEDURE MANUAL POLICIES AND PROCEDURE MANUAL Policy: MP278 Section: Medical Benefit Policy Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC) I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC) II. Purpose/Objective:

More information

ESSO Advanced Course on the Management of Soft Tissue Sarcoma (STS)

ESSO Advanced Course on the Management of Soft Tissue Sarcoma (STS) ESSO Advanced Course on the Management of Soft Tissue Sarcoma (STS) 17-19 February 2014 BERLIN In Partnership with ESSO Advanced Course on the Management of Soft Tissue Sarcoma Course Directors Chair:

More information

ESSO Advanced Course on Upper GI Robotic Surgery

ESSO Advanced Course on Upper GI Robotic Surgery ESSO Advanced Course on Upper GI Robotic Surgery 11-12 December 2016 HAMBURG ESSO Advanced Course on Upper GI Robotic Surgery Chairs Daniel Perez, University Hospital Eppendorf, Hamburg, DE Jakob Izbicki,

More information

B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51

B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51 Index Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, gastric. See also Gastric cancer. D2 nodal dissection for 57 70 Adjuvant therapy, for gastric cancer, impact of D2 dissection

More information

6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS PRELIMINARY PROGRAM. Meeting Directors:

6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS PRELIMINARY PROGRAM. Meeting Directors: 6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS Madrid, 9 th -11 th May, 2018 PRELIMINARY PROGRAM Meeting Directors: Registrations: www.mdanderson.es/embracingnewstandards

More information

4th ESSO Advanced Course on the Management of Colorectal Liver Metastases

4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 10-11 October 2016 BORDEAUX (FR) 4 th ESSO Advanced Course on the Management of Colorectal Liver Metastases Chairs Serge Evrard,

More information

ESSO-EYSAC Course on Colorectal Cancer Surgery

ESSO-EYSAC Course on Colorectal Cancer Surgery ESSO-EYSAC Course on Colorectal Cancer Surgery 21-23 January 2016 LJUBLJANA (SI) Young Surgeons & Alumni Club ESSO-EYSAC Course on Colorectal Cancer Surgery Chairs Ibrahim Edhemovic, Institute of Oncology

More information

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant

More information

ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25:

ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25: Ann Surg Oncol (2018) 25:1184 1192 https://doi.org/10.1245/s10434-018-6369-x ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal

More information

Multidisciplinary Approach to Complex Cancer & GI Surgery at CRMC

Multidisciplinary Approach to Complex Cancer & GI Surgery at CRMC Multidisciplinary Approach to Complex Cancer & GI Surgery at CRMC Babak Eghbalieh MD, FACS Associate Clinical Professor, UCSF Facility Executive Committee Chair, CRMC Amir H. Fathi, M.D. Assistant Clinical

More information

SSI Advanced Laparoscopic GI Surgery Course

SSI Advanced Laparoscopic GI Surgery Course University of Sharjah Clinical & Surgical Training Centre 19-22 Jan, 2019 Accredited by the Royal College of Surgeons of England & Association of Laparoscopic Surgeons Great Britain & Ireland(ALSGBI) Course

More information

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION VOLUME 22 NUMBER 16 AUGUST 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal

More information

Rationale for the treatment. Peritoneal Surface Malignancy

Rationale for the treatment. Peritoneal Surface Malignancy Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten

More information

Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2

Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2 Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy

More information

Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations

Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional

More information

MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018

More information

MASTERCLASS 3RD ESO-ESSO MASTERCLASS ON COLORECTAL CANCER SURGERY March 2015 Warsaw, Poland. Chairs: T. Wiggers, NL L. Påhlman, SE P.

MASTERCLASS 3RD ESO-ESSO MASTERCLASS ON COLORECTAL CANCER SURGERY March 2015 Warsaw, Poland. Chairs: T. Wiggers, NL L. Påhlman, SE P. Flyer MCC_14 Oct_screen 17.10.2014 12:34 Pagina 3 MASTERCLASS 3RD ESO-ESSO MASTERCLASS ON COLORECTAL CANCER SURGERY 7-12 March 2015 Warsaw, Poland Chairs: T. Wiggers, NL L. Påhlman, SE P. Tekkis, UK AIMS

More information

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting

More information

MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None

MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

Marcello Deraco M.D. Responsible Peritoneal Malignancies

Marcello Deraco M.D. Responsible Peritoneal Malignancies Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey

More information

This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.

This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription. Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive

More information

Peritoneal carcinomatosis cytoreductive surgery and. HIPEC - overview and basics

Peritoneal carcinomatosis cytoreductive surgery and. HIPEC - overview and basics Peritoneal carcinomatosis 1 Peritoneal carcinomatosis cytoreductive surgery and HIPEC - overview and basics BJÖRN L.D.M. BRÜCHER, MD, PhD, FACS, FRCS (Engl.) 1, POMPILIU PISO, MD, 2 VIC VERWAAL, MD, 3

More information

Enhanced Recovery after Surgery: Benefits, Challenges and Solutions for Implementation

Enhanced Recovery after Surgery: Benefits, Challenges and Solutions for Implementation Enhanced Recovery after Surgery: Benefits, Challenges and Solutions for Implementation 06-07 November 2015 MILAN (IT) IN PARTNERSHIP WITH Enhanced Recovery after Surgery: Benefits, Challenges and Solutions

More information

PRECEPTORSHIP PROGRAMME

PRECEPTORSHIP PROGRAMME esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland

More information

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma

More information

TRSGO Hands-on Course Advanced Open and Laparoscopic Gynecologic Oncology Hands-on Course for Gynecologic Oncology Fellows

TRSGO Hands-on Course Advanced Open and Laparoscopic Gynecologic Oncology Hands-on Course for Gynecologic Oncology Fellows TRSGO Hands-on Course Advanced Open and Laparoscopic Gynecologic Oncology Hands-on Course for Gynecologic Oncology Fellows Multidisciplinary Surgical Techniques On Gynecologic Oncology 6-7 th December,

More information

PROGRAMME. Henrique Prata. Director General Hospital de Amor - Barretos. Armando MELANI Scientific Director

PROGRAMME. Henrique Prata. Director General Hospital de Amor - Barretos. Armando MELANI Scientific Director PROGRAMME Henrique Prata Director General Hospital de Amor - Barretos Jacques MARESCAUX President, IRCAD University of Strasbourg, France Armando MELANI Scientific Director IRCAD Latin America Armando

More information

4th ESSO Advanced Course on the Management of Colorectal Liver Metastases

4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 10-11 October 2016 BORDEAUX (FR) 4 th ESSO Advanced Course on the Management of Colorectal Liver Metastases Chairs Serge Evrard,

More information

QUALITY INDICATORS ADVANCED (STAGE III-IV) OVARIAN CANCER SURGERY - QUALITY INDICATORS

QUALITY INDICATORS ADVANCED (STAGE III-IV) OVARIAN CANCER SURGERY - QUALITY INDICATORS ADVANCED (STAGE III-IV) OVARIAN CANCER SURGERY QUALITY INDICATORS 1 Ovarian cancer is the leading cause of death among all gynecologic cancers and remains the most common cause of death for 15 years after

More information

TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS

TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal

More information

ESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs)

ESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs) ESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs) 26-27 May 2016 LONDON (UK) ESSO Course on Diagnosis and Management of Pancreatic Neuro-Endocrine Tumours (PNETs) Chairs

More information

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH Dear Colleagues, The European School of Oncology is

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019

More information

Treatment of peritoneal metastases from colorectal cancer

Treatment of peritoneal metastases from colorectal cancer Gastroenterology Report, 3(4), 2015, 298 302 doi: 10.1093/gastro/gov044 Advance Access Publication Date: 30 September 2015 Review REVIEW Treatment of peritoneal metastases from colorectal cancer Loreen

More information

Key words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy.

Key words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy. EJSO 2001; 27: 286 290 doi:10.1053/ejso.2000.1095, available online at http://www.idealibrary.com on Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy

More information